IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Key Points

• Quarterly results: IDEAYA reported a loss of ($1.11) EPS, missing the consensus by $0.12, while revenue of $6.56 million beat estimates but fell 39.4% year-over-year.
• Stock reaction and valuation: Shares slipped to $28.31 intraday, valuing the company at about $2.49 billion with a negative P/E and a 12‑month range of $16.82–$39.28.
• Analysts and ownership: The stock carries a "Moderate Buy" consensus with an average price target of $50.44 (15 Buys), a director bought 50,000 shares at $32.96, and institutions/hedge funds own roughly 98% of the shares.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.12), FiscalAI reports. The firm had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.04 million. The firm's revenue was down 39.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.82) EPS.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ IDYA traded down $0.59 during midday trading on Tuesday, hitting $28.31. 111,001 shares of the company traded hands, compared to its average volume of 1,106,514. IDEAYA Biosciences has a 12-month low of $16.82 and a 12-month high of $39.28. The stock has a 50-day moving average price of $32.20 and a 200 day moving average price of $32.96. The firm has a market cap of $2.49 billion, a P/E ratio of -21.74 and a beta of -0.04.

Analyst Upgrades and Downgrades

Several research analysts have commented on IDYA shares. Citigroup raised their price target on shares of IDEAYA Biosciences from $64.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, February 19th. Guggenheim raised their price target on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, April 14th. Wedbush raised their price target on shares of IDEAYA Biosciences from $52.00 to $58.00 and gave the company an "outperform" rating in a report on Tuesday, April 14th. Truist Financial set a $65.00 price target on shares of IDEAYA Biosciences in a report on Monday, April 13th. Finally, Wells Fargo & Company raised their price target on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an "overweight" rating in a report on Tuesday, April 14th. Fifteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $50.44.

Insider Buying and Selling

In other news, Director Jeffrey Stein bought 50,000 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were purchased at an average price of $32.96 per share, for a total transaction of $1,648,000.00. Following the completion of the purchase, the director owned 54,281 shares in the company, valued at approximately $1,789,101.76. This represents a 1,167.95% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.50% of the stock is owned by insiders.

Hedge Funds Weigh In On IDEAYA Biosciences

Several institutional investors have recently bought and sold shares of IDYA. GSK plc purchased a new position in shares of IDEAYA Biosciences in the 4th quarter worth $46,093,000. State Street Corp grew its stake in shares of IDEAYA Biosciences by 27.6% in the 4th quarter. State Street Corp now owns 4,134,641 shares of the company's stock worth $142,935,000 after buying an additional 893,707 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of IDEAYA Biosciences by 11.8% in the 4th quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company's stock worth $248,344,000 after buying an additional 758,117 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of IDEAYA Biosciences by 43.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,770,866 shares of the company's stock worth $61,219,000 after buying an additional 537,753 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of IDEAYA Biosciences by 88.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 938,857 shares of the company's stock worth $32,456,000 after buying an additional 441,809 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.